CareDx Inc. stocks have been trading up by 22.51 percent following highly positive sentiment around its latest diagnostics developments.
Key Takeaways For CDNA Traders
- Q3 revenue around $139M–$139.4M crushed expectations near $122M, powered by CareDx’s Transplant business, Specialty Oncology growth, and pipeline advances.
- GAAP EPS climbed to $0.35 from $0.03, with adjusted EPS at $0.70, showing a sharp profit ramp.
- FY26 revenue guidance was raised to $520M–$530M and adjusted EBITDA to $90M–$100M, both well ahead of prior outlook and Street numbers.
- Canaccord and BTIG lifted CDNA price targets to $80 and $81 and reiterated Buy ratings on strong fundamentals and growth potential.
- New AlloSure Kidney and AlloSure Plus data from ASN Kidney Week 2026 reinforced CareDx’s clinical edge and biopsy‑sparing value in transplant care.
Live Update At 16:46:52 EDT: On Friday, October 30, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 22.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CDNA has turned into a momentum tape, backed by real numbers. CareDx just delivered Q3 revenue of about $139M–$139.4M, well above the $121.96M–$122.0M analyst range. For traders, that kind of beat usually means one thing: expectations were too low.
Earnings followed the same pattern. GAAP EPS jumped to $0.35 from $0.03 a year earlier, while adjusted EPS hit $0.70. That tells traders CDNA is not just growing sales; it is scaling the model and pushing more dollars to the bottom line.
You can see the reaction in the chart. CDNA closed at $69.85 on 2026/10/05 and, after some back‑and‑forth, ripped to $87.41 by 2026/10/30. That is a strong multi‑day uptrend with higher highs and higher lows. Intraday, CDNA held most of its gap, trading between the mid‑80s and just under $91, which signals dip buyers stepping in all day.
More Breaking News
- REGN Stock Climbs As Libtayo Data And Targets Rise
- No Analysis Provided
- RKT Stock Dips After Big Q3 Earnings Beat
- Global Payments Stock Climbs As Analysts Bet On Worldpay Upside
Fundamentals back up the move. CareDx runs with a fat 70.6% gross margin, low leverage, and a current ratio of 4.6, so liquidity is solid. A price‑to‑sales near 7.2 and a P/E around 30 suggest traders are already pricing in growth, but this latest quarter gives the market a reason to keep rewarding CDNA if execution continues.
Why Traders Are Watching CDNA Now
CareDx handed traders a classic catalyst combo: a big earnings beat, a bold guidance raise, and fresh clinical data to support the story. CDNA’s Q3 revenue of roughly $139M–$139.4M versus about $122M expected is not a small miss on the Street’s side; it is a reset moment. When a diagnostics name like CareDx outperforms that cleanly, algorithms and discretionary traders both notice.
The earnings quality matters. CDNA’s adjusted EPS at $0.70, on top of GAAP EPS at $0.35, shows the company is levering its transplant testing franchise and scaling newer segments like Specialty Oncology and cell therapy‑related offerings. For traders who scan for high‑growth med‑tech names breaking out, that profit ramp is fuel.
Then management doubled down with guidance. CareDx lifted its FY26 revenue outlook to $520M–$530M from $490M–$500M. It also raised FY26 adjusted EBITDA to $90M–$100M from $66M–$78M. Both metrics sit well ahead of prior Street views around $495M in revenue. For CDNA, that is management effectively telling the market, “You’re behind.”
Analysts followed. Canaccord bumped its CDNA target to $80 from $65, while BTIG went to $81 from $74, both with Buy stances and comments about underappreciated value and strong fundamentals. Whether or not traders care about the exact target, the direction is what counts. Upward revisions often attract trend followers and breakout traders.
Underneath it all, CareDx is shoring up the science. At ASN Kidney Week 2026, the company highlighted independent multinational data showing AlloSure Kidney and AlloSure Plus can strongly predict kidney transplant rejection and reduce the need for invasive biopsies, even under the newer Banff 2024 criteria. That matters for CDNA because better outcomes and fewer biopsies support reimbursement, adoption, and staying power in transplant centers.
With CDNA’s daily chart pushing into the high‑80s after a strong run from the mid‑60s, many short‑term traders are now watching for continuation moves, secondary breakouts, and potential pullback entries around prior resistance levels.
Conclusion
For active traders, CDNA is a textbook example of when strong numbers line up with a tradable chart. CareDx posted Q3 revenue well ahead of expectations, GAAP EPS of $0.35 versus $0.03 last year, and adjusted EPS of $0.70, then topped it off with FY26 revenue guidance of $520M–$530M and adjusted EBITDA of $90M–$100M. That is a clear upward reset in the story, not just a one‑off quarter.
At the same time, CareDx’s AlloSure Kidney and AlloSure Plus data from ASN Kidney Week 2026 give CDNA a real‑world edge. Reducing biopsies while keeping strong rejection prediction performance is exactly the kind of clinical value that supports long‑term revenue streams. That is why the Street is getting more constructive, with Canaccord and BTIG both hiking their CDNA targets into the $80–$81 range.
Traders still need to treat CDNA like any volatile growth name: respect risk, watch liquidity, and do not chase blindly. As Tim Sykes loves to say, “Cut losses quickly, because big losses usually start out as small ones.” That mindset lines up closely with risk‑first trading philosophies echoed by other educators; as Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.”. For educational and research purposes, CDNA now sits on many watchlists as a high‑volume earnings winner with raised guidance, bullish analyst commentary, and a strong technical uptrend that may offer both breakout and dip‑buy setups if the story holds.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.